Penumbra, Inc. (PEN) News
Filter PEN News Items
PEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PEN News Highlights
- PEN's 30 day story count now stands at 9.
- Over the past 20 days, the trend for PEN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest PEN News From Around the Web
Below are the latest news stories about PENUMBRA INC that investors may wish to consider to help them evaluate PEN as an investment opportunity.
Wall Street Analysts See a 26.89% Upside in Penumbra (PEN): Can the Stock Really Move This High?The mean of analysts' price targets for Penumbra (PEN) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Penumbra (PEN) Enrolls First Patient in Landmark STORM-PE TrialPenumbra (PEN) achieves an important milestone by enrolling the first patient in STORM-PE RCT. |
Penumbra's (PEN) Expansion Moves, New Launches Aid GrowthPenumbra (PEN) expects to materially increase both revenues and profitability of the international business in the next three years and beyond. |
First Patient in STORM-PE RCT Enrolled Evaluating Penumbra's Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash™ - for Treatment of Acute Pulmonary EmbolismPenumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, announced the first patient enrolled in STORM-PE, a first-of-its-kind prospective, multi-center, randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus Lightning Flash™ for the treatment of pulmonary embolism (PE). In partnership with PERT Consortium™, a multi-disciplinary group dedicated to improving the care of patients with PE, the STORM-PE trial aims to advance the understan |
Insider Sell Alert: EVP Johanna Roberts Sells Shares of Penumbra IncIn the intricate dance of the stock market, insider transactions often attract the attention of investors seeking clues about a company's future performance. |
Penumbra, Inc. to Present at the Piper Sandler 35th Annual Healthcare ConferencePenumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023. |
Here's Why You Should Retain Penumbra (PEN) Stock for NowInvestors are optimistic about Penumbra (PEN) on strong vascular and neuro businesses growth and upbeat guidance. |
Stocks Mixed As Bond Yields Edge HigherStocks are scattered this afternoon, after Moody's cut its U.S. credit rating outlook. |
Penumbra Teams Up with Honor Everywhere to Bring US War Memorials to Aging VeteransEveryday, memories of the people who served in World War II, Vietnam, and the Korean War are disappearing from living history. Virtual reality companies from around the world have teamed up in a program called "Honor Everywhere" to ensure the memorials are still accessible to these aging and terminally ill men and women via immersive stories. |
Penumbra (PEN) Q3 Earnings Top Estimates, Margins IncreasePenumbra's (PEN) vascular and neuro product categories continue to show encouraging growth trends. |